PMID- 15989588
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20050712
LR  - 20190917
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 6
IP  - 12
DP  - 1997 Dec
TI  - Interleukin-16 for the gene therapy of HIV infection.
PG  - 1879-81
AB  - Interleukin 16 (IL-16) has been shown to function as chemoattractant factor, as a 
      modulator of T-cell activation and as an inhibitor of human immunodeficiency 
      virus (HIV) replication. It is now clear that IL-16 is synthesised as a large 
      precursor molecule (pro-IL-16), from which as yet unidentified proteases release 
      a bioactive carboxyterminal fragment. The mechanism for IL-16 secretion is still 
      unknown, but it is likely that the secreted protein is smaller than the 
      originally published 130 amino acids. Upon transfection of an IL-16 cDNA, human 
      T-cells became virtually resistant against HIV infection. This system may well be 
      helpful in studying the mechanism of HIV suppression by this lymphokine. In 
      addition, this approach could potentially be important for the development of 
      gene therapy against HIV.
FAU - Baier, M
AU  - Baier M
AD  - Paul-Ehrlich-Institute, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany.
FAU - Kurth, R
AU  - Kurth R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
EDAT- 2005/07/02 09:00
MHDA- 2005/07/02 09:01
CRDT- 2005/07/02 09:00
PHST- 2005/07/02 09:00 [pubmed]
PHST- 2005/07/02 09:01 [medline]
PHST- 2005/07/02 09:00 [entrez]
AID - 10.1517/13543784.6.12.1879 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 1997 Dec;6(12):1879-81. doi: 
      10.1517/13543784.6.12.1879.